Treatment cuts risk of death and recurrence, but some women still go without. July 29, 2011— -- For women diagnosed with hormone-sensitive breast cancer-- more than 150,000 in the U.S. each year- ...

Response to Cyclophosphamide, Methotrexate, and Fluorouracil in Lymph Node–Positive Breast Cancer According to HER2 Overexpression and Other Tumor Biologic Variables PURPOSE: To identify predictors of ...

NEW YORK (Reuters Health) - About one third of women with breast cancer who are prescribed tamoxifen stop taking the drug well before the end of the recommended 5 years of treatment, Irish researchers ...

Only one woman out of seven with a family history of breast cancer decided to take tamoxifen as a preventive measure when it was offered, according to a small study from the United Kingdom. The ...

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. Dense breasts are not the only factor ...

An international research team has identified a previously unknown mechanism by which the breast cancer drug tamoxifen can increase the risk of secondary tumors in the uterus. Subscribe to our ...

A drug used to prevent bone-thinning fractures has just jumped to the top of the list for its ability to battle a far more lethal threat — breast cancer. Raloxifene — sold under the brand name Evista ...

Dense breasts are not the only factor increasing the risk for a breast cancer diagnosis. Family history matters, especially in a first-degree relative who was diagnosed at a young age. Younger onset ...